Home › Multipel myeloom › North Carolina › Durham
Multipel myeloom klinische studies in Durham, NC
37 studies voor Multipel myeloom zoeken deelnemers op locaties in en rond Durham (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekruterenFase 3
- Research Site, Chapel Hill · 10 mijl verwijderd
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RekruterenFase 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
RekruterenFase 2
- Duke University Medical Center, Durham
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RekruterenFase 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mijl verwijderd
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekruterenFase 3
- Durham VAMC, Durham
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
RekruterenFase 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mijl verwijderd
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekruterenFase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mijl verwijderd
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekruterenFase 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruterenFase 2
- University of North Carolina Medical Center, Chapel Hill · 10 mijl verwijderd
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RekruterenFase 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mijl verwijderd
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
RekruterenFase 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RekruterenFase 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mijl verwijderd
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RekruterenFase 1/2
- GSK Investigational Site, Chapel Hill · 10 mijl verwijderd
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekruterenFase 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekruterenFase 1/2
- Research Site, Durham
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekruterenFase 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mijl verwijderd
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Rekruteren
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mijl verwijderd
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
RekruterenFase 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RekruterenFase 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mijl verwijderd
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RekruterenFase 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mijl verwijderd
Selinexor and Backbone Treatments of Multiple Myeloma Patients
RekruterenFase 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruterenFase 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mijl verwijderd
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
RekruterenFase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mijl verwijderd
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
RekruterenFase 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mijl verwijderd
Registry of Older Patients With Cancer
RekruterenObservatieonderzoek
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mijl verwijderd
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekruterenFase 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
RekruterenFase 2
- University of North Carolina, Chapel Hill · 10 mijl verwijderd
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RekruterenFase 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mijl verwijderd
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
RekruterenFase 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mijl verwijderd
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RekruterenFase 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruterenFase 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mijl verwijderd
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekruterenFase 1
- University of North Carolina, Chapel Hill · 10 mijl verwijderd
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RekruterenFase 1
- University of North Carolina, Chapel Hill · 10 mijl verwijderd
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RekruterenFase 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mijl verwijderd
Registry for Adults With Plasma Cell Disorders (PCD's)
RekruterenObservatieonderzoek
- North Carolina Cancer Hospital, Chapel Hill · 10 mijl verwijderd
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RekruterenObservatieonderzoek
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mijl verwijderd
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RekruterenFase 1
- Duke University Health System (DUHS), Durham
Multipel myeloom studies in andere steden
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
- Seattle, WA22 studies
Andere studies in Durham
- Borstkanker63 studies
- Kanker (alle vormen)58 studies
- Niet-kleincellige longkanker39 studies
- Metastatische kanker33 studies
- Acute myeloïde leukemie33 studies
- Longkanker32 studies
- Prostaatkanker32 studies
- Colorectale kanker28 studies
- Chronische lymfatische leukemie27 studies
- Eierstokkanker27 studies
- Hartfalen26 studies
- Aldermeesklierkanker24 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.